miR-495-3p Sensitizes BCR::ABL1 Expressing Leukemic cells to Tyrosine Kinase Inhibitors by Targeting Multidrug Resistance 1 Gene including in T315I Mutated cells

Abstract excerpt

<h4>ABSTRACT</h4> Chronic myeloid leukemia (CML) is a clonal hematopoietic malignancy driven by the BCR::ABL1 fusion oncoprotein. The development of tyrosine kinase inhibitors (TKIs) has deeply increased long-term survival of CML patients. Nonetheless, one patient out of four will switch TKI off owing either to drug intolerance or resistance partly due to amplification or mutations of BCR::ABL1 oncogene and alte...

Topics

Open a Topic to create a Post that cites this publication.

• ATP Binding Cassette Transporter, Subfamily B
• Chronic Myeloid Leukemia Treatments
• Drug Resistance, Neoplasm
• Genetic Predisposition to Disease
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive
• MicroRNA in disease regulation
• Polymorphism, Single Nucleotide
• Protein Kinase Inhibitors

Identifiers and source

Literature Corpus work

9920a339-9657-5c26-a958-a656b1283dac

DOI

10.1101/2022.10.17.512501